FDA allows Curis to resume testing cancer drug

March 31, 2014 11:51 AM

22 0

(Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.

The company's shares jumped about 22 percent to $3.35 in trading before the bell.

Read more

To category page